David J. Lederer

Active 1994–2024

119
Papers
28,076
Citations
65
h-index
114
i10-index

Citations

Citations per year for David J. Lederer1993: 1 citations1995: 1 citations1997: 2 citations2002: 1 citations2003: 2 citations2004: 4 citations2005: 6 citations2006: 2 citations2007: 11 citations2008: 23 citations2009: 15 citations2010: 18 citations2011: 28 citations2012: 32 citations2013: 70 citations2014: 96 citations2015: 139 citations2016: 181 citations2017: 251 citations2018: 255 citations2019: 1,096 citations2020: 1,497 citations2021: 1,644 citations2022: 1,301 citations2023: 956 citations2024: 1,436 citations2025: 587 citations2026: 20 citations1994: no citations, so this year is not shown1996: no citations, so this year is not shown1998–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,812 citing papers, 23.8% of this breakdownChina: 1,093 citing papers, 9.2% of this breakdownUnited Kingdom: 942 citing papers, 8% of this breakdownItaly: 655 citing papers, 5.5% of this breakdownGermany: 628 citing papers, 5.3% of this breakdownCanada: 606 citing papers, 5.1% of this breakdownJapan: 543 citing papers, 4.6% of this breakdownFrance: 468 citing papers, 4% of this breakdownAustralia: 445 citing papers, 3.8% of this breakdownNetherlands: 340 citing papers, 2.9% of this breakdownSpain: 318 citing papers, 2.7% of this breakdownSouth Korea: 244 citing papers, 2.1% of this breakdown
0%23.8%Other 23%

Fields

  • Medicine84%
  • Biochemistry, Genetics and Molecular Biology7.2%
  • Immunology and Microbiology2.9%
  • Environmental Science1.5%
  • Engineering1.3%
  • Computer Science0.8%
  • Other2.3%

Topics

  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis19.4%
  • Chronic Obstructive Pulmonary Disease (COPD) Research5.2%
  • Systemic Sclerosis and Related Diseases3.9%
  • Pulmonary Hypertension Research and Treatments3.6%
  • Sarcoidosis and Beryllium Toxicity Research3%
  • Transplantation: Methods and Outcomes2.6%
  • Other62.3%

Coauthors

All papers

Open in search
  1. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Moisés Selman, William D. Travis, Simon Walsh, Kevin C. Wilson - American Journal of Respiratory and Critical Care Medicine 2018 cited by 4,100

  2. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 3,949

  3. Idiopathic Pulmonary Fibrosis

    Authors: , - New England Journal of Medicine 2018 cited by 2,030

  4. Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa A. Maier, Carlos Matiz, Ferrán Morell, Andrew G. Nicholson, Setu Patolia, Carlos A.C. Pereira, Elisabetta Renzoni, Margaret L. Salisbury, Moisés Selman, Simon Walsh, Wim Wuyts, Kevin C. Wilson - American Journal of Respiratory and Critical Care Medicine 2020 cited by 1,012

  5. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2016 cited by 1,444

  6. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

    Authors: , , , , , , , , , , - The Lancet Respiratory Medicine 2019 cited by 630

  7. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2019 cited by 286

  8. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Theodore J. Iwashyna, Gísli Jenkins, Martin Kolb, Guy B. Marks, Peter J. Mazzone, J. Randall Moorman, Thomas M. Murphy, Terry L. Noah, Paul N. Reynolds, Dieter Riemann, Richard Russell, Aziz Sheikh, Giovanni Sotgiu, Erik R. Swenson, Rhonda D. Szczesniak, Ronald Szymusiak, Jean–Louis Teboul, Jean‐Louis Vincent - Annals of the American Thoracic Society 2018 cited by 722

  9. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 267

  10. Generation and persistence of human tissue-resident memory T cells in lung transplantation

    Authors: , , , , , , , , , , , , , , , , , , , - Science Immunology 2019 cited by 294

  11. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

    Authors: , , , , , , , , , , , , , , , , - European Respiratory Journal 2015 cited by 463

  12. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2016 cited by 280

  13. A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

    Authors: , , , , , , , , , , , , , - The Journal of Heart and Lung Transplantation 2014 cited by 1,330

  14. Association Between Long-term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA 2019 cited by 396

  15. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ayodeji Adegunsoye, Mary E. Strek, Margaret Neighbors, Xuting R. Sheng, Gunnar Guðmundsson, Vilmundur Guðnason, Hiroto Hatabu, David J. Lederer, Ani Manichaikul, John D. Newell, George O'connor, Victor E. Ortega, Hanfei Xu, Tasha E. Fingerlin, Yohan Bossé, Ke Hao, Philippe Joubert, David C. Nickle, Don D. Sin, Wim Timens, Dominic Furniss, Andrew P. Morris, Krina T. Zondervan, Ian P. Hall, Ian Sayers, Martin D. Tobin, Toby M. Maher, Michael H. Cho, Gary M. Hunninghake, David A. Schwartz, Brian L. Yaspan, Philip L. Molyneaux, Carlos Flores, Imre Noth, Gísli Jenkins, Louise V. Wain - American Journal of Respiratory and Critical Care Medicine 2019 cited by 341

  16. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2013 cited by 543

  17. Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells

    Authors: , , , , , , , - Cell Reports 2019 cited by 240

  18. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2020 cited by 301

  19. Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading

    Authors: , , , , , , , , , , , - Circulation 2011 cited by 471

  20. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

    Authors: , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2016 cited by 332

  21. Delayed Access and Survival in Idiopathic Pulmonary Fibrosis: A Cohort Study

    Authors: , , , , , - American Journal of Respiratory and Critical Care Medicine 2011 cited by 308

  22. Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan R Smyth, Iain Stewart, Paul W. Stewart, Erik R. Swenson, Ronald Szymusiak, Jean–Louis Teboul, Jean‐Louis Vincent, Jadwiga A. Wedzicha, David M. Maslove - Critical Care Medicine 2020 cited by 284

  23. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Köktürk, Nesrin Moğulkoç, Christine Fiddler, Nikhil Hirani, Gísli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena Foster, Kevin F. Gibson, Marilyn K. Glassberg, Daniel J. Kass, Jonathan A. Kropski, David J. Lederer, A. Linderholm, Jim Loyd, Susan Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy Palmisciano, Cristina Reichner, Mauricio Rojas, Jesse Roman, Neil W. Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. Prêle, Juan Ignacio Enghelmayer, María Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Šterclová, Tewodros Haile Gebremariam, Marjukka Myllärniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moisés Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, María Molina‐Molina, Lurdes Planas‐Cerezales, Gunilla Westergren‐Thorsson, Albert V. Smith, Ani Manichaikul, John S. Kim and 15 more - American Journal of Respiratory and Critical Care Medicine 2023 cited by 80

  24. IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maarten van den Berge - American Journal of Respiratory and Critical Care Medicine 2023 cited by 35